Literature DB >> 29630893

Regulation of VDAC1 contributes to the cardioprotective effects of penehyclidine hydrochloride during myocardial ischemia/reperfusion.

Duomao Lin1, Boqun Cui1, Jiayue Ren1, Jun Ma2.   

Abstract

Penehyclidine hydrochloride (PHC) preconditioning can alleviate myocardial ischemia/reperfusion (I/R) injury and inhibits the upregulation of voltage-dependent anion channel 1 (VDAC1) during I/R. To validate that VDAC1 is a bona fide target of PHC for the protection against myocardial I/R injury, VDAC1 expression construct was delivered by lentiviruses into rat left ventricular myocardium before PHC preconditioning and myocardial I/R. Overexpression of VDAC1 exacerbated cardiac dysfunction and myocardial injury following I/R, and abolished the cardioprotective effect of PHC during I/R injury. Moreover, VDAC1 overexpression with myocardial I/R further increased cytochrome c release from mitochondria to cytoplasm, elevated the levels of cleaved caspase-3 and Bax, and decreased the level of Bcl-2 as compared with I/R alone, and PHC-mediated inhibition of mitochondria-dependent apoptosis during myocardial I/R was abolished by VDAC1 overexpression. In addition, VDAC1 was overexpressed in H9c2 cardiomyocytes undergoing anoxia/reoxygenation (A/R) with or without PHC pretreatment. The in vitro results showed that overexpression of VDAC1 further reduced mitochondrial membrane potential, increased mitochondrial membrane permeability and enhanced mitochondria-dependent apoptosis in H9c2 cells after A/R, and VDAC1 overexpression abrogated the protective effect of PHC on the mitochondrial function and integrity during A/R. In conclusion, exogenous overexpression of VDAC1 during myocardial I/R inhibits the cardioprotective effects of PHC. These effects may be associated with the suppression of VDAC1 expression.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Mitochondria-dependent apoptosis; Myocardial ischemia/reperfusion; Penehyclidine hydrochloride; Voltage-dependent anion channel

Mesh:

Substances:

Year:  2018        PMID: 29630893     DOI: 10.1016/j.yexcr.2018.04.004

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  7 in total

1.  Targeting calcium-mediated inter-organellar crosstalk in cardiac diseases.

Authors:  Mohit M Hulsurkar; Satadru K Lahiri; Jason Karch; Meng C Wang; Xander H T Wehrens
Journal:  Expert Opin Ther Targets       Date:  2022-04-25       Impact factor: 6.797

Review 2.  Targeting Ferroptosis against Ischemia/Reperfusion Cardiac Injury.

Authors:  José Lillo-Moya; Catalina Rojas-Solé; Diego Muñoz-Salamanca; Emiliano Panieri; Luciano Saso; Ramón Rodrigo
Journal:  Antioxidants (Basel)       Date:  2021-04-25

Review 3.  Pleiotropic effects and pharmacological properties of penehyclidine hydrochloride.

Authors:  Yaguang Wang; Yafen Gao; Jun Ma
Journal:  Drug Des Devel Ther       Date:  2018-10-05       Impact factor: 4.162

4.  Penehyclidine hydrochloride alleviates lipopolysaccharide‑induced acute respiratory distress syndrome in cells via regulating autophagy‑related pathway.

Authors:  Xiaopeng Wang; Fen Liu; Min Xu; Liangxia Wu
Journal:  Mol Med Rep       Date:  2020-12-10       Impact factor: 2.952

5.  Liproxstatin-1 protects the mouse myocardium against ischemia/reperfusion injury by decreasing VDAC1 levels and restoring GPX4 levels.

Authors:  Yansheng Feng; Ngonidzashe B Madungwe; Abdulhafiz D Imam Aliagan; Nathalie Tombo; Jean C Bopassa
Journal:  Biochem Biophys Res Commun       Date:  2019-10-14       Impact factor: 3.575

6.  Melatonin Attenuates Anoxia/Reoxygenation Injury by Inhibiting Excessive Mitophagy Through the MT2/SIRT3/FoxO3a Signaling Pathway in H9c2 Cells.

Authors:  Jinjing Wu; Yanli Yang; Yafen Gao; Zhaoqi Wang; Jun Ma
Journal:  Drug Des Devel Ther       Date:  2020-05-25       Impact factor: 4.162

Review 7.  Ferroptosis: Opportunities and Challenges in Myocardial Ischemia-Reperfusion Injury.

Authors:  Wei-Kun Zhao; Yao Zhou; Tong-Tong Xu; Qi Wu
Journal:  Oxid Med Cell Longev       Date:  2021-10-23       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.